Brokerages expect West Pharmaceutical Services Inc. (NYSE:WST) to post $433.40 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for West Pharmaceutical Services’ earnings. The highest sales estimate is $435.00 million and the lowest is $431.80 million. West Pharmaceutical Services reported sales of $415.70 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 4.3%. The company is expected to report its next earnings results before the market opens on Thursday, April 25th.
According to Zacks, analysts expect that West Pharmaceutical Services will report full-year sales of $1.81 billion for the current fiscal year, with estimates ranging from $1.80 billion to $1.82 billion. For the next financial year, analysts forecast that the firm will post sales of $1.95 billion, with estimates ranging from $1.93 billion to $1.97 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, February 14th. The medical instruments supplier reported $0.73 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.01. West Pharmaceutical Services had a return on equity of 15.89% and a net margin of 12.05%. The company had revenue of $422.50 million for the quarter, compared to analyst estimates of $432.38 million. During the same quarter in the prior year, the firm posted $0.64 EPS. West Pharmaceutical Services’s quarterly revenue was up 1.7% compared to the same quarter last year.
A number of institutional investors have recently made changes to their positions in the business. Berman Capital Advisors LLC bought a new position in shares of West Pharmaceutical Services during the 4th quarter worth $27,000. Oregon Public Employees Retirement Fund grew its position in shares of West Pharmaceutical Services by 9,703.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,836,204 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 2,807,272 shares in the last quarter. Contravisory Investment Management Inc. bought a new position in shares of West Pharmaceutical Services during the 4th quarter worth $121,000. Captrust Financial Advisors grew its position in shares of West Pharmaceutical Services by 20.7% during the 4th quarter. Captrust Financial Advisors now owns 1,339 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 230 shares in the last quarter. Finally, Pendal Group Ltd grew its position in shares of West Pharmaceutical Services by 34.5% during the 4th quarter. Pendal Group Ltd now owns 1,968 shares of the medical instruments supplier’s stock worth $193,000 after buying an additional 505 shares in the last quarter. 94.41% of the stock is currently owned by institutional investors.
NYSE:WST traded up $1.42 during midday trading on Friday, hitting $115.95. 13,036 shares of the company traded hands, compared to its average volume of 400,432. West Pharmaceutical Services has a 12-month low of $84.91 and a 12-month high of $125.09. The firm has a market capitalization of $8.45 billion, a PE ratio of 41.25, a PEG ratio of 3.63 and a beta of 1.25. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.40 and a current ratio of 3.15.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Wednesday, April 17th will be given a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.52%. The ex-dividend date is Tuesday, April 16th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.35%.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.